Stoeckel Jessica, Hay John G
New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
Curr Opin Mol Ther. 2006 Jun;8(3):249-60.
Oncolytics Biotech is developing an oncolytic reovirus therapy (Reolysin, Reosyn) for the potential treatment of a variety of Ras-mediated cancers, including glioma and medulloblastoma, pancreatic, prostate, breast, lung, colon, bladder, ovarian and hematological cancers, and melanoma and childhood sarcoma. Phase I/II clinical trials in recurrent malignant glioma began in 2002.
溶瘤生物技术公司正在研发一种溶瘤呼肠孤病毒疗法（Reolysin，Reosyn），用于潜在治疗多种由Ras介导的癌症，包括神经胶质瘤、髓母细胞瘤、胰腺癌、前列腺癌、乳腺癌、肺癌、结肠癌、膀胱癌、卵巢癌和血液系统癌症，以及黑色素瘤和儿童肉瘤。复发性恶性神经胶质瘤的I/II期临床试验于2002年开始。
